Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients

Ariba Shafiq360 enrolled

Overview

Total of 360 participants were enrolled and prescribed oral 200 mg SGLT-2 tablet. All participants were followed-up for about three months. Body mass index was measured before and after three months and mean change in BMI was assessed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

360

Conditions

Diabete Mellitus

Interventions

Oral 100 gram Empagliflozin tablet along with diet plan and exerciseDRUG

oral 100 gram Empagliflozin tablet along with diet plan and exercise

Diet plan and exerciseOTHER

Only Life style modification was advised. Changes in BMI were assessed.

Eligibility

Sex: ALLMin age: 30 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Individuals diagnosed with type II diabetes mellitus ( blood sugar level (random) at presentation was above 186 mg/dl and HbA1c was more than 6.5% on laboratory investigations) Exclusion Criteria: * Individuals already taking trail drug or any other anti-glycemic drug or insulin for \>6 months

Locations (1)

CMH Multan

Multan, Punjab Province, Pakistan

Outcomes

Primary Outcomes

Weight

Weight is measured in Kilograms

Time frame: 03 Months

Secondary Outcomes

Height

Height is measured in meters

Time frame: 03 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.